Gonorrhea testing is straightforward and usually painless. The standard test uses either a urine sample or a swab from the potentially infected area, and results typically come back within a few days. Here’s what to expect from each method and how to make sure your results are accurate.
The Standard Test: NAAT
The most common and most accurate gonorrhea test is called a nucleic acid amplification test, or NAAT. It works by detecting the bacteria’s genetic material in a sample, even when the amount of bacteria is extremely small. This makes it far more sensitive than older methods like bacterial cultures. NAATs are the go-to test at clinics, urgent care centers, and sexual health services.
There are two ways to provide a sample:
- Urine sample. You urinate into a sterile cup, collecting the very first part of your stream (called a “first-catch” sample). You’ll need to avoid urinating for at least two hours beforehand so the bacteria aren’t washed away. For men, urine testing is just as accurate as a swab. For women, urine can miss up to 10% of infections compared to a vaginal swab, so a swab is generally preferred.
- Swab sample. A provider uses a small swab or brush to collect fluid and cells from the site of potential infection, most often the vagina, urethra, or cervix. Many clinics let you swab yourself with clear instructions, which studies show works well. Swabs can also be taken from the throat, rectum, or eyes when needed.
Results from a lab-processed NAAT usually take one to five days, depending on the facility.
Where You’re Tested Depends on Exposure
Gonorrhea infects wherever it enters the body, so a genital test won’t catch an infection in your throat or rectum. Your provider will ask about your sexual history to determine which sites to test. If you’ve had oral sex, you may need a throat swab. If you’ve had receptive anal sex, a rectal swab is appropriate. Some people need samples from two or three sites in a single visit.
This matters because throat and rectal gonorrhea rarely cause noticeable symptoms. Without site-specific testing, these infections go undetected and can be passed to partners. NAATs are validated for both rectal and throat samples, though there is a small chance of false positives from the throat due to cross-reaction with related bacteria. If a positive throat result seems unexpected, your provider may run a confirmatory test.
When to Test After Exposure
Testing too early after a potential exposure can produce a false negative. The bacteria need time to multiply to detectable levels. Most infections are detectable within one week. Waiting two weeks catches nearly all cases. If you test before the one-week mark and get a negative result, consider retesting after two weeks to be sure.
Gram Stain and Culture Tests
Two older testing methods still have a role in specific situations.
A Gram stain involves examining discharge under a microscope. For men with visible urethral discharge, this method is over 95% accurate and can give a result within minutes. It’s far less reliable for women, and it doesn’t work for throat or rectal samples. It’s also not useful for men without symptoms.
A bacterial culture grows the bacteria from a swab in a lab, which takes longer (often several days) but provides one critical piece of information NAATs cannot: whether the bacteria are resistant to specific antibiotics. Cultures are ordered when treatment doesn’t seem to be working, when a provider suspects antibiotic resistance, or when a throat infection needs a follow-up “test of cure” 7 to 14 days after treatment. Antibiotic-resistant gonorrhea is a growing public health concern, making cultures increasingly important even as NAATs remain the primary screening tool.
Rapid and Point-of-Care Tests
Newer rapid tests can return results in under 30 minutes using the same NAAT technology as lab-based tests, just in a smaller, portable device. The Visby Medical Women’s Sexual Health Test, for example, uses a self-collected vaginal swab and tests for gonorrhea, chlamydia, and trichomoniasis in a single palm-sized cartridge. It received FDA clearance in 2021 for use in clinical settings, and in March 2025, it became available over the counter as the first FDA-authorized home test for these three infections.
The advantage is obvious: a diagnosis during the same visit (or at home) rather than days of waiting. The limitation is that rapid options are currently designed for vaginal swabs, so they don’t cover throat or rectal testing.
At-Home and Mail-In Testing
Beyond the Visby test, several companies sell mail-in kits where you collect a sample at home and send it to a lab. The lab technology behind these kits is generally reliable. The weak link is sample collection. Getting a good swab or urine sample requires following instructions carefully, and providers note that the quality of self-collected samples at home can vary. A poor sample can lead to a false negative, meaning a real infection goes undetected and untreated.
If you use a mail-in kit, follow the timing and collection instructions exactly. Avoid urinating for two hours before a urine test, and make sure swabs reach the correct depth. A negative result on a home test doesn’t rule out infection if you collected the sample incorrectly or tested too soon after exposure.
Who Should Get Screened Routinely
You don’t need symptoms to get tested. In fact, many gonorrhea infections, especially in women and at extragenital sites, cause no symptoms at all. The U.S. Preventive Services Task Force recommends routine gonorrhea screening for all sexually active women 24 and younger. Women 25 and older should be screened if they have risk factors such as a new partner, multiple partners, a partner with an STI, inconsistent condom use, a previous STI, or a history of exchanging sex for drugs or money.
For men, there isn’t a blanket screening recommendation from the USPSTF, though many sexual health guidelines recommend annual screening for men who have sex with men, including throat and rectal testing based on sexual practices. A reasonable approach for anyone is to test whenever your sexual history includes new or ongoing risk factors since your last negative result.